June 19, 2026
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Prescribing Qlosi for presbyopia ‘did not cannibalize optical sales’
PHOENIX — Prescribing Qlosi eye drops for presbyopia was not associated with a reduction in optical purchases or other practice performance metrics, according to a study presented here. “The questions that kept coming up among our physicians were straightforward: Is this going to hurt us? Are patients going to stop buying glasses? Are we going to see fewer billable encounters?” Harmin J. Chima,
TL;DRAI
Orasis Pharmaceuticals' Qlosi (pilocarpine 0.4%) for presbyopia posted 71.6% optical purchase rate across 111 patients vs. baseline 68.8%, proving no revenue cannibalization from presbyopia drops. Product lesson: innovative complementary solutions protect legacy revenue when positioned correctly; customers open to adoption also invest in adjacent services, not substitute.
689 words~3 min read
